EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022.
EMERALD: Updated Phase 3 Results by Duration of Prior CDK4/6i Treatment
January 23, 2023